M C Cunnington

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decade
    Marianne Morris-Cunnington
    Immunisation Division, Communicable Disease Surveillance Centre, London, UK
    Sex Transm Dis 31:243-6. 2004
  2. ncbi A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales
    M C Morris-Cunnington
    Communicable Disease Surveillance Centre, Health Protection Agency, London, UK
    Am J Epidemiol 159:786-94. 2004
  3. ncbi Immunity and exposure to hepatitis A virus in pre-adolescent children from a multi-ethnic inner city area
    M Morris-Cunnington
    Immunisation Division, Health Protection Agency, London
    Commun Dis Public Health 7:134-7. 2004
  4. ncbi Lamotrigine and the risk of malformations in pregnancy
    Marianne Cunnington
    GlaxoSmithKline, Worldwide Epidemiology, Harlow, UK
    Neurology 64:955-60. 2005
  5. ncbi Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study
    Marianne Cunnington
    GlaxoSmithKline, Harlow, Essex, United Kingdom
    Epilepsia 48:1207-10. 2007
  6. doi Risk factors for antiepileptic drug regimen change in patients with newly diagnosed epilepsy
    Marianne C Cunnington
    Worldwide Epidemiology, GlaxoSmithKline, Middlesex, UK
    Epilepsy Behav 21:168-72. 2011
  7. doi Final results from 18 years of the International Lamotrigine Pregnancy Registry
    M C Cunnington
    GlaxoSmithKline, 1 3 Iron Bridge Road, Stockley Park West, Middlesex UB111BT, UK
    Neurology 76:1817-23. 2011

Collaborators

Detail Information

Publications7

  1. ncbi New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decade
    Marianne Morris-Cunnington
    Immunisation Division, Communicable Disease Surveillance Centre, London, UK
    Sex Transm Dis 31:243-6. 2004
    ..This study aimed to ascertain trends in HSV-2 infection in England between 1991 and 2000...
  2. ncbi A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales
    M C Morris-Cunnington
    Communicable Disease Surveillance Centre, Health Protection Agency, London, UK
    Am J Epidemiol 159:786-94. 2004
    ..1% and to 12.1% in unvaccinated individuals. The availability of comprehensive risk factor data allowed the description of two risk profiles related to natural infection and vaccination...
  3. ncbi Immunity and exposure to hepatitis A virus in pre-adolescent children from a multi-ethnic inner city area
    M Morris-Cunnington
    Immunisation Division, Health Protection Agency, London
    Commun Dis Public Health 7:134-7. 2004
    ..Association with the place of birth of the child, but not that of the parent indicates that infection within this group occurs mainly abroad. Larger studies among ethnic minority groups are needed to investigate this claim further...
  4. ncbi Lamotrigine and the risk of malformations in pregnancy
    Marianne Cunnington
    GlaxoSmithKline, Worldwide Epidemiology, Harlow, UK
    Neurology 64:955-60. 2005
    ..To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry...
  5. ncbi Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study
    Marianne Cunnington
    GlaxoSmithKline, Harlow, Essex, United Kingdom
    Epilepsia 48:1207-10. 2007
    ..999, 95% CI 0.996-1.001). There was also no effect of dose, up to 400 mg/day, on the frequency of MBDs...
  6. doi Risk factors for antiepileptic drug regimen change in patients with newly diagnosed epilepsy
    Marianne C Cunnington
    Worldwide Epidemiology, GlaxoSmithKline, Middlesex, UK
    Epilepsy Behav 21:168-72. 2011
    ..2-11.3). Although a seizure during the preceding 90 days significantly increased the risk of a regimen change, it was beyond the scope of the study to determine the proportion of changes directly attributable to uncontrolled seizures...
  7. doi Final results from 18 years of the International Lamotrigine Pregnancy Registry
    M C Cunnington
    GlaxoSmithKline, 1 3 Iron Bridge Road, Stockley Park West, Middlesex UB111BT, UK
    Neurology 76:1817-23. 2011
    ..To monitor for a signal for major teratogenicity following in utero lamotrigine exposure...